Combination chemotherapy for acute nonlymphoblastic leukemia in adults. 1975

H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas

Between January 1973 and February 1975, 77 adults with acute nonlymphoblastic leukemia were treated with a combination of daunorubicin, cytosine arabinoside, 6-thioguanine, prednisone, and vincristine in university-affiliated and private institutions. After 31 patients were treated (regimen 1) the doses of all drugs were significantly increased (regimen 2). Regimes 1 and 2 yielded CR rates of 59% (17 of 29 patients) and 70% (32 of 46 patients) respectively. With regimens 2 the mean number of courses and the median number of days to CR decreased from 3 to 1.4 and from 46 to 29 respectively. Failure to achieve CR was due to persistent leukemia during regimen 1 and fatal infections during regimen 2. With regimen 2 ten of 20 patients (50%) greater than 50 years had CR compared to 22 of 26 patients (85%) less than 50 years. CR rates were similar in community and university institutions.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
September 1981, Cancer,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
March 1972, Annals of internal medicine,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
November 1982, Cancer treatment reports,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
January 1985, Haematology and blood transfusion,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
July 1983, Cancer,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
January 1983, Advances in internal medicine,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
October 1974, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
August 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
November 1984, Annals of internal medicine,
H Glucksberg, and C D Buckner, and A Fefer, and Q DeMarsh, and D Coleman, and R B Dobrow, and J Huff, and C Kjobech, and A S Hill, and W Dittman, and P E Neiman, and M A Cheever, and A B Einstein, and E D Thomas
January 1994, Acta haematologica Polonica,
Copied contents to your clipboard!